These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 14654075)
1. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Zheng R; Klang K; Gorin NC; Small D Leuk Res; 2004 Feb; 28(2):121-6. PubMed ID: 14654075 [TBL] [Abstract][Full Text] [Related]
2. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433 [TBL] [Abstract][Full Text] [Related]
3. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077 [TBL] [Abstract][Full Text] [Related]
6. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Marhäll A; Heidel F; Fischer T; Rönnstrand L Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308 [TBL] [Abstract][Full Text] [Related]
7. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia. Chougule RA; Kazi JU; Rönnstrand L Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862 [TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Zheng R; Friedman AD; Small D Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674 [TBL] [Abstract][Full Text] [Related]
9. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354 [TBL] [Abstract][Full Text] [Related]
11. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Jilani I; Estey E; Manshuri T; Caligiuri M; Keating M; Giles F; Thomas D; Kantarjian H; Albitar M Leukemia; 2003 Jan; 17(1):114-9. PubMed ID: 12529667 [TBL] [Abstract][Full Text] [Related]
12. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908 [TBL] [Abstract][Full Text] [Related]
13. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149 [TBL] [Abstract][Full Text] [Related]
14. Expression of type III receptor tyrosine kinases FLT3 and KIT and responses to their ligands by acute myeloid leukemia blasts. Stacchini A; Fubini L; Severino A; Sanavio F; Aglietta M; Piacibello W Leukemia; 1996 Oct; 10(10):1584-91. PubMed ID: 8847893 [TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983 [TBL] [Abstract][Full Text] [Related]
16. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608 [TBL] [Abstract][Full Text] [Related]
17. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Rombouts WJ; Blokland I; Löwenberg B; Ploemacher RE Leukemia; 2000 Apr; 14(4):675-83. PubMed ID: 10764154 [TBL] [Abstract][Full Text] [Related]
18. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Lisovsky M; Estrov Z; Zhang X; Consoli U; Sanchez-Williams G; Snell V; Munker R; Goodacre A; Savchenko V; Andreeff M Blood; 1996 Nov; 88(10):3987-97. PubMed ID: 8916965 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064 [TBL] [Abstract][Full Text] [Related]
20. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]